Research and Markets: Global Alzheimers Drugs Market 2014-2018 with Eisai Co. Forest Laboratories, Janssen Pharmaceuticals & Novartis Dominating

The incidence rates for Alzheimer’s disease are increasing, and the global Alzheimer’s population is expected to double by 2030.

Currently, it is estimated that 5 million Americans suffering from Alzheimer’s disease are aged 65 years or above. This number might reach 13.8 million by 2050 as the baby boom generation ages. In the US, Alzheimer’s disease is the fifth highest cause factor for deaths among people aged 65 years and above. It has been recognized as the only factor among the top 10 death-causing factors in America for which therapy is not available, preventing or slowing down the progression of disease. The number of deaths resulting from Alzheimer’s disease increased by 68 percent during the period of 2000-2010 and this number is expected to increase further during the next decade. In the US, it is estimated that about 7,00,000 people aged 65 years or above will die from Alzheimer’s disease in 2014. The incidence rate of Alzheimer’s disease is increasing rapidly owing to a rise in the elderly population. In the US, the 2014 incidence rate of Alzheimer’s disease for people aged 65 years or above is expected to reach 4,69,000 and this number is expected to double by 2050.

According to the report, the Global Alzheimer’s Drugs market is driven by several factors, of which the increase in the global aging population is one of the major drivers. The incidence of Alzheimer’s disease is growing continuously, mainly because of an increase in the aging population, especially those aged 65 years or above. It is estimated about 596.8 million people will reach 65 years and above in 2014, and this number is expected to reach 681.2 million by 2018.

Furthermore, the report states that one of the main challenges is the poor rate of Alzheimer’s disease diagnosis. In developed economies, merely 20-50 percent of dementia cases are diagnosed while in developing economies such as India nearly 90 percent cases remain undiagnosed. The lack of diagnosis hampers the effective management of this disease.